Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide (1.38 million cancer deaths, 18.2% of the total) and of cancer morbidity (1.61 million new cases, 12.7% of all new cancers). Currently only three second-line non-small-cell lung cancer (NSCLC) pharmacotherapies are licensed in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwander, Bjoern, Ravera, Simona, Giuliani, Giovanni, Nuijten, Mark, Walzer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435091/
https://www.ncbi.nlm.nih.gov/pubmed/22969300
http://dx.doi.org/10.2147/CEOR.S34371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435091/
https://www.ncbi.nlm.nih.gov/pubmed/22969300
http://dx.doi.org/10.2147/CEOR.S34371

Ejemplares similares